A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.
A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progressionon Osimertinib.
Sponsor: Memorial Sloan Kettering Cancer Center
Listed as NCT03755102, this EARLY_PHASE1 trial focuses on EGFR Gene Mutation and Lung Cancer and remains completed. Sponsored by Memorial Sloan Kettering Cancer Center, it has been updated 15 times since 2018, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
15 versions recorded-
Jun 2025 — Present [monthly]
Completed EARLY_PHASE1
-
Sep 2024 — Jun 2025 [monthly]
Completed EARLY_PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed EARLY_PHASE1
-
Aug 2023 — Jul 2024 [monthly]
Completed EARLY_PHASE1
Status: Active Not Recruiting → Completed
-
Dec 2022 — Aug 2023 [monthly]
Active Not Recruiting EARLY_PHASE1
Status: Recruiting → Active Not Recruiting
▶ Show 10 earlier versions
-
Sep 2022 — Dec 2022 [monthly]
Recruiting EARLY_PHASE1
-
Sep 2021 — Sep 2022 [monthly]
Recruiting EARLY_PHASE1
-
Mar 2021 — Sep 2021 [monthly]
Recruiting EARLY_PHASE1
-
Jan 2021 — Mar 2021 [monthly]
Recruiting EARLY_PHASE1
-
May 2020 — Jan 2021 [monthly]
Recruiting EARLY_PHASE1
-
Oct 2019 — May 2020 [monthly]
Recruiting EARLY_PHASE1
-
Jul 2019 — Oct 2019 [monthly]
Recruiting EARLY_PHASE1
-
Jun 2019 — Jul 2019 [monthly]
Recruiting EARLY_PHASE1
-
May 2019 — Jun 2019 [monthly]
Recruiting EARLY_PHASE1
-
Dec 2018 — May 2019 [monthly]
Recruiting EARLY_PHASE1
First recorded
Nov 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Memorial Sloan Kettering Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .